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ABSTRACT
The Saccharomyces cerevisiae Rad1-Rad10 complex
is a conserved, structure-specific endonuclease im-
portant for repairing multiple types of DNA lesions.
Upon recruitment to lesion sites, Rad1-Rad10 re-
moves damaged sequences, enabling subsequent
gap filling and ligation. Acting at mid-steps of repair,
the association and dissociation of Rad1-Rad10 with
DNA can influence repair efficiency. We show that
genotoxin-enhanced Rad1 sumoylation occurs after
the nuclease is recruited to lesion sites. A single ly-
sine outside Rad1’s nuclease and Rad10-binding do-
mains is sumoylated in vivo and in vitro. Mutation of
this site to arginine abolishes Rad1 sumoylation and
impairs Rad1-mediated repair at high doses of DNA
damage, but sustains the repair of a single double-
stranded break. The timing of Rad1 sumoylation and
the phenotype bias toward high lesion loads point to
a post-incision role for sumoylation, possibly affect-
ing Rad1 dissociation from DNA. Indeed, biochemi-
cal examination shows that sumoylation of Rad1 de-
creases the complex’s affinity for DNA without affect-
ing other protein properties. These findings suggest
a model whereby sumoylation of Rad1 promotes its
disengagement from DNA after nuclease cleavage,
allowing it to efficiently attend to large numbers of
DNA lesions.
INTRODUCTION
Structure-specific nucleases occupy a central position in
DNA repair due to their ability to remove a wide range
of damaged sequences and resolve joint DNA structures in
the genome. Consequently, they greatly influence genome
stability and cell survival upon exposure to environmental
mutagens and cancer therapeutic drugs. Optimized nucle-
ase function in vivo is achieved by multiple layers of regu-
lation. Many structure-specific nucleases interact with and
are regulated by other repair factors that help recruit the nu-
cleases to specific DNA lesion sites or stimulate their activ-
ities (1–4). In addition, many nucleases are modified post-
translationally (4–19). A few detailed studies show that dy-
namic and reversible protein modifications can alter nucle-
ase activities or protein levels in order to meet specific cell
cycle needs for DNA cleavage (11–16). However, the effects
of many of these proteinmodifications on nucleases are cur-
rently unknown.
Recent studies have revealed that a large number of DNA
repair proteins, including several nucleases, are sumoylated
in response to DNA damage in yeast and humans (7–9,20).
Although sumoylation as a whole can increase DNA repair
capacity (7,20–25), it is unclear how this is achieved at the
level of each substrate and what principles underlie SUMO-
mediated regulation of DNA repair. A comprehensive un-
derstanding of these questions requires detailed studies of
sumoylation’s effects on each target. Here we look into the
role of sumoylation in regulating the Rad1 nuclease in bud-
ding yeast. Rad1 forms a heterodimer with Rad10, which
is required for Rad1 catalytic activity on branched DNA
substrates (26–28). Rad1-Rad10 and their human homologs
XPF-ERCC1 can remove several types of DNA lesions,
such as those generated by UV radiation, topoisomerase
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inhibitors and DNA break-inducing agents (1,29). Their
important physiological roles are highlighted by the asso-
ciation of XPF-ERCC1 mutations with cancer-prone dis-
eases, including xeroderma pigmentosum, Cockayne syn-
drome and Fanconi anemia (30–32).
In yeast, Rad1-Rad10 acts in nucleotide excision repair
(NER) to remove bulky DNA lesions, such as those in-
duced by UV (29). DNA distortion generated by these le-
sions is recognized by the NER factors Rad4 and Rad23
(33–35). A pre-incision complex is subsequently formed at
lesion sites to unwind theDNA surrounding the lesion, gen-
erating a bubble structure (29,36,37). The Rad14 protein
of this pre-incision complex recruits Rad1-Rad10 to DNA
bubbles via direct physical interaction (38,39). Dual inci-
sions by Rad1-Rad10 and another nuclease, Rad2, at the
5′ and 3′ ends of the bubble, respectively, remove lesion-
containing fragments (40,41). This allows subsequent re-
pair synthesis and ligation. Besides involvement in NER,
Rad1-Rad10 also acts as a back-up nuclease to remove
protein-DNA adducts generated by the Top1 inhibitor
camptothecin (CPT) (42,43). Moreover, Rad1-Rad10 func-
tions in single-strand annealing (SSA) repair of double-
stranded breaks, where its cleavage of 3′ flaps enables subse-
quent ligation (44,45). Recruitment and nucleolytic activity
of Rad1-Rad10 in SSA are regulated by the lesion-binding
factor Saw1 and the scaffolding protein Slx4, respectively
(46–48).
Here, we determined that Rad1 is sumoylated on a sin-
gle lysine and generated an unsumoylatable rad1 allele. Ex-
amining the phenotype of this mutant and the timing of
modification in vivo, in conjunction with in vitro analysis
of the sumoylated Rad1 protein, suggests that sumoylation
of Rad1 promotes repair efficiency, most likely by enhanc-
ing the dissociation of Rad1-Rad10 from DNA after nucle-
olytic cleavage.
MATERIALS AND METHODS
Yeast strains and genetic manipulations
Strains used are listed in Table 1. Standard yeast protocols
were used for strain generation, growth, medium prepara-
tion and DNA damage sensitivity assays. As siz1Δ siz2Δ
results in amplification of 2-micron plasmids (49), strains
with siz1Δ siz2Δ mutations were cured of the plasmid as
described (50). Spot assays were performed as described
previously (7). Briefly, log phase cells were diluted 10-fold
or 3-fold and spotted onto YPD (Yeast extract-Peptone-
Dextrose) media with or without CPT, or irradiated with
UV. Plates were incubated at 30◦C and photographed after
24–72 h.
Detection of sumoylated proteins and immunoprecipitation
These were performed as described previously (7). In brief,
cells were lysed by bead beating under denaturing condi-
tions and TAP-tagged proteins were immunoprecipitated
using immunoglobulin G (IgG)-Sepharose. These were
then washed and eluted with loading dye, followed by
sodium dodecylsulphate-polyacrylamide gel electrophore-
sis (SDS-PAGE) and western blotting with antibodies
against SUMO (22) and the protein A portion of the TAP
tag (Sigma-Aldrich). Damage-induced sumoylation was as-
sayed by subjecting log-phase cells to 0.03–0.3% methyl-
methane sulfonate (MMS, Sigma-Aldrich), 50 ug/ml CPT
(Sigma-Aldrich), or 0.2 M hydroxyurea (HU, US Biologi-
cals) for 2 h, or UV irradiation using UV Stratalinker 1800
(Stratagene). For Figure 1A,UV andMMSdoses were cho-
sen based on comparable survival posttreatment as shown
in Supplementary Figure S1A–B. Co-immunoprecipitation
experiments were performed as described previously (51).
SSA assays
Chromosomal and plasmid-based SSA assays were per-
formed as described (46). In brief, for chromosomal assay,
log-phase cells grown in YP-Glycerol were plated on ei-
ther YPD or YP-Galactose media. Only the latter induces
HO expression, and thus double -strand break formation
and SSA repair. Colonies were counted after incubation at
30◦C for 3–4 days. SSA survival quantification was done
by dividing the number of viable colonies on YP-galactose
plates by that on YPD and multiplying this factor by 100.
For plasmid-based assay, cells were transformed with either
Bsu36I- ormock-digested pNSU208 plasmid, plated onme-
dia lacking leucine and incubated at 30◦C for 3–4 days. Per-
cent survival estimating SSA efficiency was calculated by
dividing number of viable colonies of the Bsu36I-digested
transformants by those of mock-digested ones.
Rad1-Rad10 protein expression, purification and gel filtra-
tion
The Escherichia coli strain Rosetta(DE3)pLysS was trans-
formed with a bicistronic plasmid (gift from Dr. Steve
Brill (52)) expressing (His)6-Rad1 and Rad10, or (His)6-
Rad1-K32R and Rad10. The Rad1-K32R mutant was
generated using site-directed mutagenesis. Protein expres-
sion was induced by 0.1 mM IPTG (Isopropyl -D-1-
thiogalactopyranoside) at 16◦C overnight. A total of 9 g of
cell paste was sonicated in 40 ml breakage buffer (50 mM
Tris-HCl, pH 7.5, 10% sucrose, 2 mM ethylenediaminete-
traacetic acid (EDTA), 200 mM KCl, 0.01% NP40, 1 mM
-mercaptoethanol and protease inhibitor cocktail contain-
ing pepstatin, aprotinin, benzamidine, chymostatin and le-
upeptin). The lysate was clarified by centrifugation (100k
g, 4◦C, 1 h), and the supernatant was incubated with 1 ml
of HIS-Select nickel affinity gel (Sigma) for 1 h at 4◦C. The
beadswerewashedwith 12ml of bufferK (20mMK2HPO4,
10% glycerol, 0.5mMEDTA) containing 150mMKCl. The
bound proteins were eluted with buffer containing 50 mM
KCl and imidazole (from 50 to 1000 mM). Pooled fractions
containing Rad1-Rad10 (150–500 mM imidazole) were ap-
plied to a 1-ml Heparin column (GE Healthcare) followed
by elution using 8 ml gradient of 275–1000 mM KCl in
buffer K. The peak fractions of Rad1-Rad10 at ∼500 mM
KCl elution were pooled, loaded onto a 0.5-ml MonoQ
column (GE Healthcare) and eluted using a 5-ml gradient
of 275–1000 mM KCl in buffer K. The Rad1-Rad10 frac-
tions were concentrated to 400 l in a VivaSpin-2 concen-
trator, and fractionated on a 23-ml Sephacryl S400 column
(GEHealthcare) in K buffer containing 300 mMKCl. Peak
Rad1-Rad10 fractions were concentrated to 2 g/l. To
Nucleic Acids Research, 2014, Vol. 42, No. 10 6395
Table 1. Yeast strains used in this study
Strain Genotype Source
W1588-4A Mat alpha leu2-3,112 ade2-1 can1-100
his3-11,15 ura3-1 trp1-1 RAD5
R. Rothstein
T581 Mat a RAD1-TAP::HIS This study
X3456-2C Mat a RAD1-TAP::HIS rad14Δ::KAN This study
X3711-1B RAD1-TAP::HIS rad4Δ::KAN This study
X3527-9A RAD1-TAP::HIS saw1Δ::KAN This study
X3539-8B Mat alpha RAD1-TAP::HIS slx4Δ::KAN This study
X3527-1A Mat a RAD1-TAP::HIS rad14Δ::KAN
saw1Δ::KAN
This study
X3458-1A Mat alpha RAD1-TAP::HIS rad52Δ::KAN This study
X3526-13B Mat alpha RAD1-TAP::HIS rad14Δ::KAN
rad52Δ::KAN
This study
T1302-2 Mat a rad1-D825A-TAP::HIS This study
T908-2 Mat alpha rad1-D869A-TAP::HIS This study
X3563-1B Mat alpha rad1-D869A-TAP::HIS
saw1Δ::KAN
This study
X3541-10D Mat alpha rad1-D869A-TAP::HIS
rad14Δ::KAN
This study
X3541-10A Mat alpha rad1-D869A-TAP::HIS
rad52Δ::KAN
This study
X3629-20A RAD1-TAP::HIS mec1Δ::TRP sml1Δ::HIS This study
X3580-12A Mat alpha RAD1-TAP::HIS siz1Δ::KAN cir0 This study
X3580-4C Mat a RAD1-TAP::HIS siz2Δ::URA cir0 This study
X3201-6D RAD1-TAP::HIS mms21-11::HIS cir0 This study
X3580-5C Mat alpha RAD1-TAP::HIS siz1Δ::KAN
siz2Δ::URA cir0
This study
X3401-1C Mat alpha rad1Δ::LEU This study
X3840-6B rad1-K32R-TAP::HIS This study
X5692-7A RAD1-TAP::HIS apn2Δ::HIS This study
X3919-2D rad1-K32R-TAP::HIS apn2Δ::HIS This study
X6004-1B rad1Δ::LEU apn2Δ::HIS This study
X4373-17A RAD1-TAP::HIS tdp1Δ::KAN This study
X3916-1C rad1-K32R-TAP::HIS tdp1Δ::KAN This study
X3404-2D rad1Δ::LEU tdp1Δ::HIS This study
X3727-1A RAD1-TAP::HIS RAD10-13Myc::KAN This study
X3840-5C rad1-K32R-TAP::HIS RAD10-13Myc::KAN This study
X3729-1A RAD1-TAP::HIS RAD14-13Myc::KAN This study
X4491-5A rad1-K32R-TAP::HIS RAD14-13Myc::KAN This study
X4965-2C RAD1-TAP::HIS SAW1-FLAG::KAN This study
X4966-9A rad1-K32R-TAP::HIS SAW1-FLAG::KAN This study
X4489-1C RAD1-TAP::HIS SLX4-3HA::KAN This study
X4490-1B rad1-K32R-TAP::HIS SLX4-3HA::KAN This study
X3728-1A RAD10-13Myc::KAN This study
X4491-3B RAD14-13Myc::KAN This study
X4965-2B SAW1-FLAG::KAN This study
X4489-1B SLX4-3HA::KAN This study
SLY5151 EAY1141 ho HML mat::leu2::hisG hmrΔ3
leu2-3,112 ura3-52 trp1
THR4-ura3-A(205bp)-HOcs-URA3-A
ade3::GAL10-HO::NAT
This study
SLY5136 SLY5151 rad1-K32R-3HA::HYG This study
Yeast strains are listed in Table 1. Strains in this study except SSA strains are derivatives of W1588–4C, a RAD5 derivative of W303.
Thomas, B.J. and Rothstein, R. (1989) Elevated recombination rates in transcriptionally active DNA. Cell, 56, 619–630.
Sugawara, N., Goldfarb, T., Studamire, B., Alani, E. and Haber, J.E. (2004) Heteroduplex rejection during SSA requires Sgs1 helicase and mismatch repair
proteins Msh2 and Msh6 but not Pms1. Proc. Natl. Acad. Sci. U. S. A., 101, 9315–9320.
determine the oligomeric status of Rad1-Rad10, a 23 ml
Sephacryl S400 columnwas elutedwith bufferK containing
300 mMKCl (0.11 ml/min flow rate), and 0.35 ml fractions
were collected. The indicated fractions were separated by
SDS-PAGE and detected by western blotting using -Rad1
antibody (Santa Cruz).
In vitro sumoylation assay
Purification of GST-Aos1/Uba2, His-Ubc9, His-Flag-
Smt3, His-Flag-Smt3-KR, His-Siz1 (1–465) and Siz2 and
the sumoylation assay were performed as previously (53).
In brief, the 10 l reaction contained 150 nM Aos1/Uba2,
0.5 M Ubc9, 4.3 M Smt3 or Smt3-KR, 0.4 M Rad1-
Rad10, 1 mM adenosine triphosphate (ATP) and buffer S1
(100 mMTris-HCl pH 7.5, 10 mMMgCl2) (53). In the indi-
cated cases, 10–100 nM Siz1 or 10–100 nM Siz2 was added
to the reaction.
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Figure 1. DNA damage-induced sumoylation of Rad1 occurs upon recruitment to lesion sites. (A) Rad1 sumoylation is induced by UV, MMS and CPT,
but not HU treatment. TAP-tagged Rad1 was immunoprecipitated from yeast strains untreated or treated with 100 J/m2 UV, 50 ug/ml CPT, 0.2 MHU or
0.2% MMS and was western blotted for SUMO (top) and Protein A (bottom). Note that in the SUMO blot, the lower band representing the unmodified
form arises from interaction of the nonspecific region of the antibody with the Protein A (ProA) portion of TAP (7). (B–D) Rad1 sumoylation induction
requires upstream NER and SSA factors. Cells containing Rad1-TAP and indicated mutations were treated with 200 J/m2 UV (B) or 0.3% MMS (C–D)
and examined as in (A). (E–G) Hypersumoylation of nuclease dead Rad1-D825A (−nd1) and Rad1-D869A (−nd2) depends on upstream NER and SSA
factors. Cells containing indicated mutations were examined as in (B–C). In (E) and (F), the relative ratios of modified to unmodified forms were quantified
using the band intensities from the SUMO blot and are shown below. Different intensities of unmodified and sumoylated Rad1 bands on different blots
are due to variable antibody quality and exposure time.
DNA substrates
All substrates were prepared as described (54). Synthetic
oligonucleotides were purchased from VBC Biotech; se-
quences are available upon request.
Electrophoretic mobility shift assay (EMSA)
Rad1-Rad10was incubatedwith fluorescently labeledDNA
substrates (4 nM) in 10 l buffer D (40 mM Tris-HCl, pH
7.5, 50 mMKCl, 1 mM DTT and 100 g/ml bovine serum
albumin) at 37◦C for 10 min. The reactions were stopped
by adding loading buffer (60% glycerol, 10 mMTris, pH 7.4
and 60mMEDTA). Samples were separated on native poly-
acrylamide gel (10%) in 0.5×TBE buffer (40 mM Tris-HCl,
20 mM boric acid, 2 mM EDTA, pH 7.5). DNA was visu-
alized by a scanner FLA9000 Starion (Fujifilm) and quan-
tified using MultiGauge software (Fujifilm).
Nuclease assay
Rad1-Rad10was incubatedwith fluorescently labeledDNA
substrate (4 nM) in 10l bufferR (50mMTris-HCl, pH 7.5,
1 mM MgCl2, 1 mM DTT and 100 g/ml bovine serum
albumin). The reaction mixtures were incubated at 30◦C
for 30 min and deproteinized by adding 0.1% SDS and 500
g/ml of proteinase K for 5 min at 37◦C. Samples were re-
solved on a 10% native polyacrylamide gel in TBE buffer.
The fluorescent DNA species were visualized as in EMSA.
RESULTS
Rad1 sumoylation is enhanced by DNA damaging agents and
requires Rad1 recruitment to DNA lesions
Recent proteomic and biochemical screens have identified
Rad1 as one of the sumoylation targets during the DNA
damage response (7,8,20). We confirmed Rad1 sumoyla-
tion in our W303 strain background using endogenously
expressed and functional TAP-tagged Rad1 (Figure 1A,
and data not shown). The sumoylated form of Rad1 was
detected as a single band above the unmodified protein
band on western blots when immunoprecipitated Rad1 was
examined with anti-SUMO antibody (Figure 1A). Rad1
sumoylation was observed under normal growth conditions
and an increase was seen upon exposure to UV, the alkyla-
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tion agent MMS and the Top1 poison CPT (Figure 1A and
Supplementary Figure S1C). Treatment with the ribonu-
cleotide reductase inhibitor HU that is not known to re-
quire Rad1-mediated repair had no effect (Figure 1A). We
note that even upon UV, MMS and CPT exposure, only a
small proportion of Rad1 was sumoylated, as the modified
Rad1 band was barely detectable on blots probed with anti-
tag antibody after short exposures.We conclude that a small
fraction of Rad1 is mono-sumoylated and this modification
is enhanced by UV, MMS and CPT treatment.
The low level of Rad1 sumoylation and its DNA dam-
age inducibility raised the possibility that Rad1 is sumoy-
lated only in specific situations, such as when the protein
is actively engaged in DNA repair. We addressed this pos-
sibility by examining whether Rad1 sumoylation depended
on its recruitment to lesions. Under UV treatment, Rad14
recruits Rad1-Rad10 to DNA lesions by physical interac-
tion (38). We found that rad14Δ greatly reduced the level of
Rad1 sumoylation (Figure 1B). We also examined whether
Saw1, a Rad1 recruitment factor in SSA (46,47), influences
its sumoylation. Since SSA mutants are most sensitive to
MMS treatment, we conducted the test in MMS and found
that saw1Δ also reduced Rad1 sumoylation (Figure 1C).
Residual sumoylation in rad14Δ and saw1Δ cells likely re-
flects Rad1 recruitment to DNA lesions by the remaining
factor. Indeed, rad14Δ saw1Δ double mutants exhibited
further reduction of Rad1 sumoylation than either single
mutant (Figure 1D).
As Rad14 and Saw1 both recruit and form complexes
withRad1-Rad10, the observedRad1 sumoylation decrease
could be due to either impaired recruitment or impaired
complex formation in their absence. To discern if Rad1-
Rad10 recruitment per se is important for Rad1 sumoyla-
tion, we examined more upstream NER and SSA proteins
that are necessary for Rad1-Rad10 recruitment but do not
physically interact with the nuclease. In NER, Rad1 recruit-
ment to UV lesions requires the lesion recognition factor
Rad4, which does not bind to Rad1-Rad10 (55). We found
that rad4Δ, like rad14Δ, reduced Rad1 sumoylation (Fig-
ure 1B), suggesting that it is the presence of Rad1 at DNA
lesions that is essential for its sumoylation. Similarly, in mu-
tants of the SSA factor Rad52, which is required for forma-
tion of 3′ flaps and Rad1 recruitment but does not phys-
ically interact with Rad1 (44), we also detected reduced
Rad1 sumoylation, as in saw1Δ cells (Figure 1D). Also as in
saw1Δ cells, the residual sumoylation in rad52Δwas largely
dependent on Rad14, as the rad52Δ rad14Δ double mu-
tant showed a further decrease in Rad1 sumoylation (Fig-
ure 1D), consistent with both NER and SSA contributing
to the repair of MMS lesions. Taken together, the reduction
in Rad1 sumoylation in mutants lacking twoNER proteins,
Rad4 and Rad14, and two SSA proteins, Saw1 and Rad52,
suggests that the initiation of repair and subsequent recruit-
ment of Rad1-Rad10 to DNA lesions are required for Rad1
sumoylation.
Mutations blocking Rad1-mediated cleavage affect Rad1
sumoylation
The above results suggest that Rad1 sumoylation occurs
after it is recruited to DNA lesions. Next we addressed
whether DNA lesion recruitment is sufficient to induce
Rad1 sumoylation, using the slx4Δmutant. Slx4 is required
for Rad1 nucleolytic cleavage but not its recruitment to
3′ flaps during SSA (46,47,56). In slx4Δ cells, Rad1 is re-
cruited to SSA lesions but cannot initiate cleavage (46,47).
We found that slx4Δ reducedRad1 sumoylation similarly to
saw1Δ (Figure 1C). This effect suggests that Rad1 sumoy-
lation requires an Slx4-dependent step after DNA lesion as-
sociation.
To test if nucleolytic cleavage is required for sumoyla-
tion, we used two nuclease dead Rad1 mutants. The D825A
mutant (Rad1-nd1) lacks a conserved catalytic residue and
is trapped on DNA (46), and the D869A mutant (Rad1-
nd2) corresponds to D720A in XPF that shows no nu-
clease activity in vitro (42,57). Interestingly, both catalytic
site mutations increased Rad1 sumoylation, as relative lev-
els of SUMO-Rad1 over unmodified forms were higher in
rad1-nd1 and –nd2 cells than in wild-type (Figure 1E and
F). Moreover, both mutants showed additional sumoylated
Rad1 species (Figure 1E and F). The increased sumoyla-
tion still depended on Rad1 recruitment to DNA lesions
as it was reduced in mutants of upstream NER and SSA
factors, including Rad14, Saw1 and Rad52 (Figure 1G).
This result, in conjunction with our other data, suggests
that Rad1 sumoylation occurs at lesion sites and requires an
Slx4-dependent step but not Rad1-Rad10 nucleolytic activ-
ity.
Sumoylation of Rad1 after DNA damage is Mec1-
independent and requires the Siz ligases
Several aspects of DNA repair are regulated by the DNA
damage checkpoint (58,59). However, we have previously
shown that the DNA damage-induced sumoylation of nu-
merous proteins is checkpoint-independent, indicating that
this sumoylation response is largely separable from the
phosphorylation-based checkpoint pathway (7,60). To un-
derstand if Rad1 sumoylation follows this rule or is an ex-
ception, we analyzed its sumoylation in the absence of the
main checkpoint kinase Mec1. As shown in Figure 2A, the
level of Rad1 sumoylation was the same in mec1Δ cells as
in wild-type after treatment with UV or MMS. Thus, we
conclude that damage-induced sumoylation of Rad1, as for
many other repair proteins, is not dependent on Mec1.
Yeast, like most organisms, contains only one SUMO
E2, but multiple mitotic SUMO E3 ligases. Yeast E3 lig-
ases include the homologous Siz1 and Siz2 proteins, and
the more distant Mms21. The Siz enzymes, and sometimes
Mms21, show redundancy in sumoylation of various sub-
strates (61,62). To understand whether Rad1 sumoylation
is dependent on a particular E3 or can be carried out by re-
dundant E3s, we examined single and double E3 mutants in
vivo. We found that none of the single E3 mutants affected
Rad1 sumoylation level (Figure 2B). For combinatorial E3
mutants, only the siz1Δ siz2Δ double mutant significantly
decreased Rad1 sumoylation, while combining the siz single
mutations with mms21–11, which lacks the Mms21 ligase
domain, resulted in smaller decreases (Figure 2C and D).
The redundancy of the two Siz proteins is consistent with
the observation that the siz1Δ siz2Δ double mutant, but
neither single mutant, is sensitive to UV and MMS ((7,20)
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Figure 2. Sumoylation induction of Rad1 is dependent on Siz1 and Siz2 but not Mec1. (A) Rad1 sumoylation upon MMS and UV treatment does
not require Mec1. Rad1-TAP from wild-type or mec1Δ strains was assayed as in Figure 1B and C. (B–D) Siz1 and Siz2 primarily contribute to Rad1
sumoylation in vivo. Cells containing Rad1-TAP and indicated mutations were assayed as in Figure 1B and C. (E) Coomassie stain showing purified His-
tagged recombinant Rad1-Rad10 and Rad1-K32R-Rad10 complexes. (F) Rad1 sumoylation is stimulated by the Siz1 and Siz2 ligases in vitro. Reactions
were incubated with increasing concentrations of Siz enzymes (10–100 nM) for 1 h at 30◦C and analyzed by 10% SDS–PAGE, followed by western blotting
with antibodies against Rad1 (top) and SUMO (bottom).
and data not shown). Thus, the three E3s are redundant in
sumoylating Rad1 in vivo, with Siz1 and Siz2 playing promi-
nent roles.
To test Siz-dependent sumoylation in vitro, we purified
recombinant Rad1-Rad10, as well as SUMO machinery
proteins, including SUMO (Smt3), E1 (Aos1/Uba2), E2
(Ubc9) and the Siz E3s, as previously described ((53), Fig-
ure 2E and data not shown). As shown in Figure 2F, Siz1
or Siz2 can efficiently sumoylate Rad1 in the presence of
ATP. In both cases, a single Rad1 sumoylation band was
detected by antibodies against Rad1 or SUMO on west-
ern blots. These observations are consistent with our in vivo
findings, indicating that Rad1 can be sumoylated by both
Siz ligases. We note that in vitro sumoylation requirements
are more relaxed than in vivo, likely due to the high con-
centration of sumoylation machinery components (63–65).
Consistent with this, the presence of DNA and/or Saw1 did
not appear to affect Rad1 sumoylation (data not shown).
Rad1 sumoylation occurs on a single lysine in vivo and in vitro
Despite the less stringent requirements for Rad1 sumoyla-
tion in vitro, the similar sumoylation patterns and the same
Siz E3 dependence in vitro and in vivo suggested that in
vitro sumoylated Rad1 can be informative for determin-
ing the sumoylation site using mass spectrometry. This ex-
periment identified lysine 32 as the sumoylation site with
high confidence (P < 0.05, Supplementary Figure S2). K32
lies within a sumoylation consensus motif (KxE/D, where
 is a hydrophobic amino acid, (66,67)). This residue in
the N-terminal region of the protein is far from Rad1’s
nuclease domain and the helix–hairpin–helix (HhH) do-
main involved in interaction with Rad10 and DNA (Fig-
ure 3A). The Rad1 N-terminal domain has not been stud-
ied in detail, though the same region in the human ho-
molog,XPF, contributes toDNA interaction (68). Thus, the
Rad1 sumoylation site localizes to a region likely involved
in DNA binding.
To verify that K32 is indeed the bona fide sumoylated ly-
sine, we first purified a recombinant K32R mutant of the
Rad1 protein and subjected it to in vitro sumoylation. As
shown in Figure 3B, wild-type Rad1, but not the K32Rmu-
tant, can be sumoylated in the presence of ATP. We then
tested if K32R also abolishes sumoylation in vivo, by in-
troducing the K32R mutation at the endogenous RAD1 lo-
cus and assaying sumoylation. rad1-K32R eliminated Rad1
sumoylation under both UV and MMS conditions (Figure
3C), confirming that K32 is the Rad1 sumoylation site in
vivo.
The rad1-K32Rmutant shows sensitivity to high doses of UV
and CPT, but is proficient for repair of a single DNA break
Next, we examined how lack of Rad1 sumoylation affects
cell survival in the presence of genotoxins. We first queried
the UV sensitivity of cells expressing the nonsumoylatable
rad1-K32R allele using both spotting and plate-out assays.
In both assays, blocking Rad1 sumoylation decreased re-
sistance to high doses of UV (Figure 3D and E), with an
estimated reduction of ∼20% in the survival of rad1-K32R
cells compared to wild-type cells (P < 0.05).
We did not detect increased sensitivity of rad1-K32R
to other types of DNA damaging agents, including CPT,
MMS and HU (data not shown). As Rad1 acts in a back-
up pathway for CPT repair and its sumoylation is induced
by CPT treatment ((42); Figure 1A), we examined if rad1-
K32R affects resistance to this drug when other proteins in-
volved in this repair are absent. Like rad1Δ but to a less de-
gree, rad1-K32R sensitized cells lacking Tdp1, a phosphodi-
esterase that processes the majority of CPT lesions ((42,69);
Figure 3F). As reported previously, rad1Δ did not sensitize
cells lacking Apn2, an endonuclease that functions in base
excision and CPT repair, as well as in processing blocked
DNA ends with Rad1 (43,70,71); unexpectedly, rad1-K32R
showed sensitization (Figure 3F). It is possible that un-
sumoylated Rad1 prevents downstream or other repair in
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Figure 3. Rad1 is monosumoylated atK32 and its sumoylation contributes toUV andCPT repair. (A) Schematic depictingRad1 domains and sumoylation
site. HhH denotes helix–hairpin–helix. (B) Rad1-K32R is not sumoylated in vitro. Proteins purified as in Figure 2E were assayed for sumoylation as in
Figure 2F. (C)rad1-K32R abolishes Rad1 sumoylation in vivo. Rad1-TAP from wild-type or rad1-K32R cells was assayed as in Figure 1B and C. (D and
E)rad1-K32R is sensitive to UV at high doses. Spot assay showing 3-fold serial dilutions of yeast strains either untreated or treated with indicated UV doses
(D). Survival curves after exposure to the indicated UV doses is presented based on 5 independent trials; averages and standard deviations are shown (E).
Asterisks denote statistically significant differences. (F)rad1-K32R sensitizes tdp1Δ and apn2Δ to CPT. Spot assay showing 10-fold serial dilutions of yeast
strains on indicated media. (G and H)rad1-K32R is not defective in chromosomal (G) and plasmid-based (H) SSA assays. Assays measuring SSA between
205 bp ura3 repeats on yeast chromosome V (G) or plasmid pNSU208 carrying 240 bp of directly repeated LacZ sequences (H). Survival of wild-type and
rad1-K32R derivative upon HO induction is shown.
the absence of Apn2 (see Discussion). In both tdp1Δ and
apn2Δ backgrounds, rad1-K32R sensitization was observed
only at high CPT doses (Figure 3F).
The manifestation of rad1-K32R’s effects at high drug
doses suggests that sumoylation influences aspects of Rad1
function that becomemore critical when the lesion burden is
large. To test this idea, we examined how rad1-K32R affects
the repair of a single double-strand break via SSA. Rad1-
Rad10 cleaves at the ds-ssDNA junction in this process as
in NER and CPT repair. If the above idea were correct,
one would expect that rad1-K32R is proficient for repair-
ing a single break. We used two well-established SSA assays
where a double-strand break is generated either on a plas-
mid or at a chromosomal locus by the HO endonuclease
(46). As the HO cut site is flanked by two complementary
sequences, repair of the break ismediated by SSA.We found
that rad1-K32R was proficient for SSA repair of both plas-
mid and chromosomal breaks, based on survival rates after
HO induction (Figure 3G-H). Taken together, the pheno-
type of rad1-K32R supports the notion that Rad1 sumoyla-
tion becomes more important when large numbers of DNA
lesions need to be repaired.
Lack of Rad1 sumoylation affects neither its protein interac-
tions nor its nuclease activity
To gain a molecular understanding of the effect of Rad1
sumoylation and of the reason underlying the rad1-K32R
phenotype, we examined Rad1 protein properties in several
ways. First, rad1-K32R did not affect Rad1 protein levels
under normal and genotoxin conditions (Figure 4A; data
not shown). Second, Rad1-K32R behaved similarly to wild-
type Rad1 in DNA binding assays (Supplementary Figure
S3A and B). Third, rad1-K32R did not affect interaction
with Rad10, as wild-type and mutant Rad1 proteins exhib-
ited similar levels of Rad10 association in vitro and in vivo
(Figures 2E and 4B). Additionally, the gel filtration pro-
files of unmodified and sumoylated Rad1 in complex with
Rad10 were similar, with sumoylated Rad1 being eluted in
the same fractions as the unmodified protein (Figure 4C).
Thus, we conclude that the sumoylation status of Rad1 does
not affect Rad10 interaction. We note that the gel filtration
profiles of Rad1-Rad10 proteins are consistent with a dimer
of heterodimers with an apparent molecular mass of 300
kDa (Figure 4C), though further work is necessary to gain
a detailed understanding of this potential oligomerization.
Next, we examined Rad1 protein interactions important
for its recruitment and/or nuclease activity. First, we tested
Rad1 interactionwithRad14 afterUV treatment, asNER is
critical for UV repair. No difference was seen between Rad1
and Rad1-K32R in their ability to pull down Rad14 pro-
tein after UV treatment (Figure 4D). Similar results were
obtained when wild-type Rad1 and the K32R mutant were
assessed for Saw1 or Slx4 interactions (Figure 4E and F).
Note that the Slx4 band shift afterMMS treatment was seen
as previously reported and is due to phosphorylation of the
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Figure 4. Rad1 sumoylation affects neither Rad1 protein levels nor its protein–protein interactions. (A)rad1-K32R does not affect Rad1 or Rad10 protein
levels. Rad1-TAP and Rad10-Myc protein levels in crude extracts from wild-type and rad1-K32R mutant cells were assayed by western blotting with
antibodies against corresponding tags. (B, D–F) Rad1-K32R is proficient for interaction with Rad10, Rad14, Saw1 and Slx4 in vivo. Extracts from cells
containing indicated tagged proteins treated with MMS or UV were immunoprecipitated with IgG-Sepharose to pull down Rad1-TAP, and probed by
western blot using antibodies against either the corresponding tag or Saw1. Note that in (D), the faint Rad14 band present in the untagged Rad1 sample
(first lane) is due to nonspecific binding of Rad14-Myc to the resin. The Rad14-Rad1 interaction is manifested in the increased amount of Rad14 pulled
down from Rad1-TAP compared with untagged Rad1. (C) Sumoylated Rad1 has the same gel filtration profile as unmodified protein. Recombinant Rad1-
Rad10 was assayed by gel filtration before and after being subjected to sumoylation reaction. Molecular markers are indicated below the gel filtration
profiles.
protein (72). The reason for lower levels of Slx4 pulled down
after MMS treatment is unclear, though it could be due to
either reduced Slx4-Rad1 interaction or less efficient detec-
tion. Nevertheless, the Rad1-K32R mutant behaved simi-
larly to the wild-type protein in its ability to interact with
Slx4 in this assay (Figure 4F). Taken together, we conclude
that Rad1-K32R is proficient for interactions with Rad14,
Saw1 and Slx4, suggesting that sumoylation of Rad1 does
not cause major changes in protein–protein interactions.
To test the effect of sumoylation on Rad1 nuclease ac-
tivity, we compared the activity of equal amounts of wild-
type Rad1-Rad10 with the K32R variant complex on Y-
form substrates. The fluorescently labeled DNA cleavage
product migrated faster than the reactant on gels and the
mutant complex exhibited activity similar to its wild-type
counterpart (Supplementary Figure S3C). We also opti-
mized our in vitro sumoylation system such that ∼80% of
Rad1 was sumoylated (Figure 5A). When we compared
equal amounts of sumoylated and unmodifiedRad1 in these
cleavage assays, again, no difference was detected (Figure
5B). As control reactions that contain only the sumoylation
reaction proteins did not show any nuclease activity (Sup-
plementary Figure S4A), the cleaved product was produced
by sumoylated Rad1, rather than other components of the
sumoylation reaction. We note that the presence of 20% un-
modified Rad1 may exclude the detection of small effects of
sumoylation. Together, these results show that neither the
lack of Rad1 sumoylation nor using a protein prep contain-
ing predominantly sumoylated Rad1 affects nuclease activ-
ity.
Sumoylation of Rad1 decreases its affinity for dsDNA and
Y-forms
Our in vivo data suggest that Rad1 sumoylation occurs af-
ter DNA lesion recruitment and that the modification be-
comes more important when dealing with large numbers of
DNA lesions. Both observations suggest that sumoylation
may aid the release of Rad1 from the product after nuclease
cleavage. Thus, we examined whether sumoylation of Rad1
favors DNA dissociation.
We tested the interaction of unmodified and sumoylated
Rad1-Rad10 with both Y-form DNA and dsDNA, which
mimic the substrate and product of the nucleolysis reac-
tion, respectively. We found that unmodified Rad1-Rad10
binds to both dsDNA and Y-forms (Figure 5C and D). Al-
though Rad1-Rad10 is thought to be released from DNA
after cleavage simply by intrinsic differences in the enzyme’s
affinity for different forms of DNA, we found that Rad1-
Rad10 interaction with dsDNA is only slightly weaker than
that with Y-forms. This result suggests that additional regu-
lation exists to enable efficient dissociation of Rad1-Rad10
from dsDNA. Consistent with this, the excised oligomer in
NER is released at a faster rate in vivo than in vitro (73), im-
plying the existence of regulatory mechanisms specifically
for achieving shorter turnaround times in NER in vivo.
When sumoylated Rad1 obtained as above was assayed,
we detected a reproducible decrease in affinity for both Y-
forms and dsDNA, compared with unmodified Rad1 (Fig-
ure 5C–E). This is not due to the sumoylation reaction com-
ponents, as this mixture did not show DNA association
(Supplementary Figure S4B and C). In addition, the effect
of sumoylatedRad1 is notmimicked byRad1-K32R-Rad10
in combination with free SUMO (Supplementary Figure
S4D andE), suggesting that only theRad1-conjugated form
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Figure 5. Rad1 sumoylation leads to decreased affinity for DNA but does not affect nuclease activity. (A) Rad1 sumoylation reaction in vitro. s.p. denotes
sumoylation reactionmixture without Rad1-Rad10. (B) SumoylatedRad1 complexed with Rad10 has the same nuclease activity onY-forms as the unmodi-
fied complex. Increasing concentrations of sumoylated (lanes 6–9) and nonsumoylated (lanes 2–5) Rad1-Rad10 proteins (0.06–1.2 nM) were incubated with
Y-form DNA (4 nM) and assayed as described in Methods. (C–E) Sumoylated Rad1 complexed with Rad10 exhibit decreased affinity for Y-forms (C) and
dsDNA (D). Increasing concentrations of sumoylated (lanes 6–9) and nonsumoylated (lanes 2–5) Rad1–10 proteins (5–50 nM) were tested. Quantification
of several binding trials is shown in (E); Rad1–10 denotes Rad1-Rad10. Asterisks indicate statistically significant differences. (F) Model: Sumoylation of
Rad1 promotes dissociation of the Rad1-Rad10 complex from the cleavage product. This effect likely occurs in NER (depicted), CPT and SSA repair (not
shown). Details in Discussion.Discussion.
of SUMO exerts the observed effect on DNA association.
We also found that sumoylated Rad1 exhibited less bind-
ing to 5′ overhang, but not ssDNA, compared to unmodi-
fied Rad1 (Supplementary Figure S4F–H). It is conceivable
that the observed sumoylation-mediated reductions in affin-
ity for the product of the cleavage reaction enable efficient
disengagement of Rad1-Rad10 from DNA postcleavage.
DISCUSSION
The Rad1-Rad10 nuclease and homologs are involved in
multiple DNA repair pathways and are tightly regulated
at the levels of recruitment and activation. Despite the ad-
vances in understanding the regulation of this important
type of nucleases, the full picture of how they can efficiently
attend to large numbers of DNA lesions via multiple path-
ways has been unclear. Here, we show that budding yeast
Rad1 is modified by SUMO after recruitment to lesion
sites. Lack of Rad1 sumoylation leads to cellular sensitivity
to high doses of DNA damage. These results suggest that
sumoylation may affect Rad1 function by enabling efficient
recycling of the enzyme.Our biochemical studies provide di-
rect evidence that sumoylation of Rad1 reduces its associa-
tion with DNA but does not affect other protein properties.
Together, these findings suggest a new regulatory mode for
Rad1-Rad10 whereby sumoylation promotes Rad1’s DNA
dissociation.
Several lines of evidence support the idea that Rad1
sumoylation occurs at DNA lesion sites. First, only a small
fraction of Rad1 is sumoylated and only DNA damaging
agents that elicit Rad1-mediated repair enhance its sumoy-
lation (Figure 1A). These results hint that the timing of
Rad1 sumoylation is strictly regulated. Second, and impor-
tantly, sumoylation of Rad1 largely depends on proteins
that recruit it to DNA lesion sites (Figure 1B–D). These
data strongly suggest that Rad1 needs to be present at sites
of damage in order to be sumoylated. Third, Rad1 sumoy-
lation exhibited a strong dependence on Slx4 (Figure 1C),
which affects the nucleolysis step after Rad1 recruitment.
This further delineates the timing of Rad1 sumoylation to
an Slx4-dependent step after lesion recruitment. Finally,
nuclease-dead Rad1 that is trapped at lesion sites is hyper-
sumoylated (Figure 1E and F), suggesting that sumoylation
does not require catalysis per se but rather increases as the
inactive protein associates longer with DNA.
Rad1 sumoylation requires either of the two homologous
Siz SUMO ligases in vivo or in vitro (Figure 2). The lack of
specific ligase could mean that the SUMO E2 plays impor-
tant roles in determining the modification site. Mass spec-
trometry identification of the sumoylation site, as well as in
vitro and in vivo confirmation (Figure 3B and C and Sup-
plementary Figure S2), show that Rad1 is sumoylated at
K32, which is within the E2 substrate-recognition site (67).
The K32 residue is located outside the Rad1 nuclease and
Rad10-binding domains, but is within a domain implicated
in DNA association in XPF (68). This location fits with the
proposed effect of sumoylation (see below).
The nonsumoylatable rad1-K32Rmutant exhibited mod-
erate UV sensitivity only at high doses (Figure 3D and E),
suggesting that sumoylation of Rad1 may be particularly
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useful when large numbers of lesions are present. Consistent
with this notion, rad1-K32R sensitized tdp1Δ and apn2Δ at
high doses of CPT (Figure 3F). This phenotype bias toward
large lesion loads is in line with normal repair of a single
DNA break in rad1-K32R cells (Figure 3G and H). A sim-
ple explanation of the phenotype is that high lesion loads
demand the efficient recycling of the enzyme, a feature not
so important for the repair of a single lesion.
Our biochemical results show that while sumoylation
does not alter Rad1 protein levels, protein interactions or
nuclease activity, it causes a decrease in DNA binding affin-
ity (Figures 4 and 5), consistent with the location of the
modified lysine in a putative DNA association domain. In-
tegrating these biochemical findings with our other results,
a plausible model is that sumoylation facilitates the disen-
gagement of Rad1 from DNA after nuclease cleavage (Fig-
ure 5F). Although sumoylation of Rad1 reduced binding
to both dsDNA (product) and Y-forms (substrate) in vitro,
only the former likely has functional consequences in vivo,
as Rad14 and Saw1 may dictate Rad1-Rad10 binding to
DNA substrates. We envision that alterations occur in the
following steps mediated by Slx4, such that Rad1-Rad10
can better access the substrate DNA and become amenable
for sumoylation. Subsequently, sumoylation could impact
Rad1-Rad10’s affinity for the dsDNA product of the reac-
tion, facilitating its release, thus contributing to the timely
repair of large numbers of lesions. Our data do not exclude
other possible effects of Rad1 sumoylation in DNA repair.
For example, sumoylation could reduce the interaction of
Rad1-Rad10 with dsDNA at other regions, thus providing
a ‘sweeping’ mechanism to disfavor unproductive DNA as-
sociation or impedance of other repair pathways, as sug-
gested by the genetic interaction with apn2Δ. As Rad1 is
not an abundant protein but is required for multiple repair
pathways, ensuring high turnover may well be important
for Rad1 function in the cell. Further biochemical work is
needed to elucidate how sumoylation of Rad1 promotes its
dissociation from DNA; for example, sumoylation may in-
duce a conformational change in the N-terminal domain of
Rad1 leading to decreased DNA binding ability, similar to
the case of sumoylation of TDG (thymine-DNA glycosy-
lase), a human base excision repair enzyme (74,75).
The mild effect of sumoylation on Rad1 function seen
here is not an exception, rather it adds to a growing list
of cases where sumoylation of DNA repair substrates has
moderate but functional effects (53,76–81). These accumu-
lating findings point to the possibility that sumoylation
wields a strong influence on DNA repair by collectively ex-
erting small changes on the functions of many proteins. We
thus propose that at least part of the SUMO-dependent
DNAdamage response ismediated by a ‘group effort’ where
SUMO moderately alters many protein functions all at
once, rather than by a ‘star effect’ hinging on only a few key
targets. These two strategies have different biological impli-
cations: the former offers a well-buffered and, therefore, ro-
bust system for coping with large numbers of DNA lesions,
whereas the latter ismore sensitive to perturbations and also
implies a waste of cellular resources as more substrates are
modified than necessary. Importantly, we highlight that the
‘group effort’ strategy entails diverse functional alterations
of protein-DNA or protein–protein interactions or enzy-
matic activities, and not solely by providing molecular glue.
Further studies of additional sumoylation substrates will be
able to thoroughly test the above notions.
In summary, our results reveal a new contribution of
sumoylation to achieve efficient DNA repair by targeting
Rad1, and suggest a new way to regulate nucleases by
sumoylation. Considering that XPF, the human homolog
of Rad1, is sumoylated upon stress (10), and plays multiple
important roles in DNA repair, it will be interesting to de-
termine whether sumoylationmakes similar functional con-
tributions in human cells.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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